For children who suffer from epilepsy and other seizure disorders, there may be a new treatment option approved by the FDA in the near future. The drug Epidiolex, which is derived from cannabidiol (CBD), is the first FDA-sanctioned drug to undergo several clinical trials for the purpose of examining its effects on children who suffer from intractable seizure disorders. The American Academy of Neurology released very encouraging preliminary results from the trials. Data revealed that over 50 percent of 137 epileptic children and young adults who were treated with Epidiolex for a period of three months saw a reduction in their seizures.

These results are only preliminary, and should not be taken as hard scientific proof yet, but now there is research that seems to support what people have been saying all along: medical marijuana can reduce seizures in children. The clinical trials for Epidiolex will continue for several months, and the complete results of the trials should be available next year.

CannaBest Medical

CannaBest Medical is the developer of the world's first Medical Marijuana dosing app. The CannaBest Medical App provides a data driven system which allows users to safely and rapidly achieve the best therapeutic outcomes from cannabinoid therapy.

The CannaBest Medical App gives users access to information generated from user responses in the form of interactive media. It is not able to provide personal medical advice, nor is it designed to diagnose disease. Users should only begin Cannabinoid therapy when recommended by a physician.